Participants will receive one of the two treatments for a defined period and will undergo two imaging procedures: a scan called 18F-FDG PET/CT, which shows how the heart uses sugar, and a scan named 99mTc-Tetrofosmin SPECT, which visualizes blood flow in the heart. These scans are performed at the beginning of the study and after the treatment phase to compare changes. Throughout the study, participants will attend regular visits for safety checks and to collect information about heart function and blood flow.

The purpose of the study is to see if Orforglipron is as effective as Dapagliflozin in managing blood sugar levels. Participants will be randomly assigned to receive either Orforglipron or Dapagliflozin, both taken as capsules by mouth once a day. Some participants may receive a placebo, which looks like the real medication but does not contain the active ingredient. The study will monitor changes in blood sugar levels over time to assess the effectiveness of the treatments.

Throughout the study, participants will have regular check-ups to monitor their health and the effects of the medication. The study aims to provide valuable information on how well Orforglipron works compared to Dapagliflozin in people with Type 2 Diabetes who are already taking Metformin. This research could help improve treatment options for managing blood sugar levels in individuals with this condition.

Both medicines are given as a subcutaneous injection, which means an injection under the skin, once a week. People in the study receive one of several dose plans of NNC0487-0111 or semaglutide, and some study groups receive placebo. The study follows changes in body weight, blood sugar, waist size, blood pressure, and other health measures over time. It also looks at side effects, including low blood sugar, which can happen when blood sugar drops too far.

The study is planned to run for a long period, with treatment and follow-up visits spread across the study time. The medicines are given in a pre-filled pen, and the course of the study is designed to compare how the different treatments work and how safe they are in adults with excess body weight and type 2 diabetes.

People in the study receive one of several weekly dose levels of NNC0487-0111 or placebo. The treatment is given with a pre-filled pen and the study lasts for many months. During the study, body weight, blood sugar control, and other health changes are followed, along with any unwanted effects.

The study is designed to find out whether NNC0487-0111 can help reduce body weight in people who have excess body weight and type 2 diabetes. It also looks at changes in waist size, blood sugar, blood pressure, blood fats, and quality of life, as well as safety issues such as low blood sugar and other side effects.

Participants in the study may receive cagrilintide alone, the combination of cagrilintide and semaglutide, semaglutide alone, or a placebo. The study involves monitoring changes in Body Mass Index, which is a measurement used to determine if a person has a healthy weight for their height, and the BMI Standard Deviation Score, a calculation that compares a person’s body mass to the average for others of the same age and sex. The course of the study involves weekly injections over a period of time to observe how these substances affect body weight and overall health.

The purpose of this study is to evaluate the safety and how well the body tolerates multiple doses of ALN-4324 in patients with Type 2 Diabetes Mellitus. The study will also look at how effective the medication is in controlling blood sugar and how the body processes the medication. Safety will be checked by monitoring any unwanted effects, measuring vital signs like blood pressure and heart rate, performing heart tests called ECGs, and doing blood tests in the laboratory.

The study is divided into two parts and will involve giving either ALN-4324 or placebo to participants. In one part, healthy volunteers who are overweight or have obesity will receive a single dose, while in the other part, patients with Type 2 Diabetes Mellitus who are overweight or have obesity will receive multiple doses over time. During the study, doctors will measure changes in a blood test called HbA1c, which shows average blood sugar levels over several months, and will also look at how the body responds to sugar by measuring insulin and glucose levels. Blood samples will be taken to measure how much ALN-4324 is in the body. The study will last for several months, and participants will need to attend regular visits for monitoring and testing.

The main goal of the study is to see how well CagriSema works at lowering blood sugar levels compared to semaglutide alone, as measured by a blood test called HbA1c that shows average blood sugar over several months. The study will also look at how these medications affect body weight, blood pressure, cholesterol levels, and other health measurements. Researchers want to understand if the combination medication works better than the individual medications at helping people reach target blood sugar levels and lose weight. The study will also measure how much time blood sugar levels stay within a healthy range using a continuous glucose monitor, which is a small device that tracks sugar levels throughout the day.

Participants will receive their assigned treatment for 68 weeks, with the entire study lasting about 75 weeks. During this time, they will have regular visits to check their blood sugar, weight, blood pressure, and overall health. The study will also ask participants questions about their quality of life and satisfaction with their diabetes treatment. Safety will be carefully monitored throughout the study, including checking for side effects and episodes of low blood sugar, which can occur when blood sugar drops too low and may cause symptoms like shakiness or confusion.

The purpose of this study is to find out if CagriSema can improve markers that show how chronic kidney disease is progressing in people with type 2 diabetes who are living with overweight or obesity. Participants may also be taking other medicines during the study, such as enalapril maleate, dapagliflozin propanediol, or finerenone, which are used to help protect the kidneys and manage related conditions. The study will measure changes in urine protein levels, kidney function, body weight, waist size, blood sugar control, and blood pressure. It will also track any side effects or health problems that occur during treatment.

During the study, participants will receive their assigned treatment for up to 35 weeks. They will attend regular visits where measurements will be taken and blood and urine samples will be collected to check how well the treatment is working and to monitor safety. The study team will look at changes from the start of the study to the end of treatment to understand the effects of each treatment option.

The purpose of this study is to find out if CagriSema can lower blood sugar levels and reduce body weight better than placebo in people with type 2 diabetes who are managing their condition with diet and exercise but still have blood sugar levels that are too high. The study will measure changes in a blood test called HbA1c, which shows average blood sugar levels over time, and will also look at changes in body weight and other health measurements.

People taking part in this study will receive either CagriSema at different dose levels or placebo once a week for 40 weeks. The treatment is given as an injection under the skin. During the study, regular visits will be scheduled to check blood sugar levels, body weight, blood pressure, and other health markers. Blood tests will be done to measure various substances in the blood, and questionnaires will be used to understand how participants feel about their energy levels and satisfaction with treatment. After the treatment period ends, there will be a follow-up period of 12 weeks to continue monitoring participants.

The purpose of the study is to find out if the combination treatment of cagrilintide semaglutide is better than placebo at lowering blood sugar levels in people with type 2 diabetes who are already using basal insulin with or without metformin. The study will also look at how the treatment affects body weight and other health measures. The main treatment period will last 40 weeks, during which participants will receive either the combination treatment at different dose levels or placebo through weekly injections under the skin.

During the study, doctors will measure blood sugar control by checking HbA1c, which is a blood test that shows average blood sugar levels over the past few months. They will also measure changes in body weight, waist size, blood pressure, and various blood tests including cholesterol and other fats in the blood. The study will track how much insulin participants need to use and whether they experience low blood sugar episodes. Participants will also complete questionnaires about their satisfaction with treatment and their energy levels. Safety will be monitored throughout the study by recording any unwanted effects that occur.

The purpose is to determine if using both medications together works better than empagliflozin alone in preventing serious heart-related health issues in people with these three conditions. The study will particularly look at how well this combination prevents death from heart problems and reduces the need for hospital visits due to heart failure.

Participants in this study will receive treatment for about 51 months. During this time, they will take either the combination of both medicines or empagliflozin with a placebo. Their blood pressure, kidney function, and heart health will be monitored throughout the study period. The medications being tested are designed to help manage blood sugar levels and blood pressure while protecting the heart and blood vessels.

The administration of RJVA-001 involves a procedure known as endoscopic ultrasound-guided delivery. During this process, a specialized medical tool is used to guide the medication directly into the pancreas, the organ responsible for regulating blood sugar. Participants in the study will receive a single dose of the treatment, and the study will observe how different dose levels affect the body to ensure the process is safe.

Participants in the study will be assigned to receive either CX11 tablets or a placebo. The study follows a randomized and double-blind design, meaning that participants and researchers do not know which treatment is being given to which person. The investigation also looks at other factors such as FPG, which is the measurement of blood sugar after fasting, and changes in body weight and blood pressure.

The purpose of the study is to evaluate how different forms and doses of semaglutide affect the way blood clots in these specific groups. One group of participants will use Rybelsus, which is an oral tablet, while another group may use Wegovy, which is a subcutaneous injection, meaning it is administered through a needle just under the skin. Some participants will receive a placebo or compare these treatments against existing medications like acetylsalicylic acid.

During the study, participants will follow a specific treatment plan involving either tablets or injections over a set period. Researchers will monitor various biological markers, including indicators of inflammation and how well the blood vessels are functioning, to observe changes in the body’s response to the medications.

Participants in the study will receive either the test medication NNC0662-0419, a comparator drug named Ozempic, or a placebo. The study will monitor changes in HbA1c, which is a blood test that shows the average blood sugar levels over the past few months. Additionally, changes in body weight will be observed during the course of the research.

The study compares the effects of different treatment options. One group may receive a combination of Obicetrapib and Ezetimibe in a single tablet, while another group receives Obicetrapib alone. Other participants may receive a placebo. Throughout the course of the study, participants will take these tablets daily to see how they influence various types of cholesterol and other related markers in the blood.

The purpose of the study is to see how well Tirzepatide works compared to Dulaglutide in reducing major cardiovascular events, such as heart attacks or strokes, in people with Type 2 Diabetes who are at high risk for heart problems. Participants in the study will receive either Tirzepatide or Dulaglutide, along with their usual diabetes care, to see which treatment is more effective in preventing these serious heart-related events.

The study will take place over a period of time, during which participants will receive regular injections of either Tirzepatide or Dulaglutide. The researchers will monitor the participants’ health to track any occurrences of heart-related events. The goal is to determine if Tirzepatide is not only as effective as Dulaglutide but also if it might be superior in preventing major cardiovascular events in people with Type 2 Diabetes.

The purpose of the study is to evaluate the long-term effectiveness and safety of Tirzepatide in adults who are starting treatment early in their Type 2 Diabetes journey. Participants will be monitored for changes in their blood sugar levels, specifically looking at Hemoglobin A1c (HbA1c), which is a common measure of blood sugar control. The study will last for about 104 weeks, during which participants will receive either Tirzepatide or the intensified conventional care.

Throughout the study, participants will receive regular check-ups to monitor their health and the effectiveness of the treatment. The goal is to determine if Tirzepatide can provide a similar or better outcome in managing Type 2 Diabetes compared to the traditional methods. This research aims to offer insights into new treatment options for individuals with this condition.

Participants will receive one injection of the vaccine into a muscle. Blood samples will be taken before the vaccination and again 14 days after the vaccination to measure the level of antibodies, which are proteins that help fight off infections. The study will check how many people reach a protective level of antibodies and how many people have a significant increase in antibody levels after vaccination. The vaccine contains inactive flu virus particles that cannot cause the flu but help the body build protection against it.

During the study, any side effects will be recorded, including reactions at the injection site such as pain or redness, and general symptoms like fever or tiredness that may occur in the week after vaccination. Any serious health problems or unexpected reactions will also be monitored throughout the entire study period. The study will compare the vaccine response between different groups including people with obesity, people with obesity and diabetes, people with normal weight, and pregnant women with and without obesity.

The purpose of the study is to find out if cagrilintide semaglutide is at least as good as tirzepatide at lowering blood sugar levels, and whether it might be better at helping people lose weight. The study will also look at other health measures such as blood pressure, waist size, cholesterol levels, and overall quality of life. Additionally, the study will check how safe these medications are and what side effects people may experience while taking them.

People taking part in this study will receive either cagrilintide semaglutide or tirzepatide for 60 weeks. During this time, they will continue taking their current diabetes medications. Throughout the study, participants will have regular visits where their blood sugar levels, body weight, blood pressure, and other health measurements will be checked. Blood tests will be done to measure a substance called HbA1c, which shows average blood sugar levels over the past few months, as well as cholesterol and other blood fats. Participants will also be asked to complete questionnaires about their physical health and quality of life. The study team will monitor for any side effects, including episodes of low blood sugar, which can happen when blood sugar drops too much.

The study will last for 40 weeks. During this time, participants will receive either the weekly IcoSema injection or the daily Ryzodeg injection. The study will measure changes in blood sugar control by looking at a blood test called HbA1c, which shows average blood sugar levels over time. This measurement will be taken at the beginning of the study and again after 40 weeks to see how much it has changed. The study will also look at other factors such as changes in body weight, the number of times blood sugar drops too low (called hypoglycaemic episodes), the amount of insulin needed each week, and how satisfied participants are with their treatment.

Throughout the study, additional information will be collected including blood sugar measurements taken at different times of the day, time spent with blood sugar levels outside the target range, and quality of life scores. The study will also track how the treatment affects daily life and overall wellbeing using questionnaires. Both treatment options will be given as injections under the skin, and the doses may be adjusted during the study to help achieve the best blood sugar control for each participant.

The study will test two different medications to see how they affect insulin resistance in the heart. The first medication is semaglutide, which is given as an injection under the skin and belongs to a group of medicines called GLP-1RA. The second medication is dapagliflozin propanediol, which is taken by mouth as a tablet and belongs to a group of medicines called SGLT2i. Both of these medications are already used to treat type 2 diabetes, but this study wants to learn more about how they work specifically on the heart muscle.

During the study, participants will receive one of these medications for a period of 16 weeks. The researchers will use special imaging tests to look at the heart and measure how well it uses sugar for energy and how blood flows through the heart. These tests include 18F-FDG PET/CT and 99mTc-Tetrofosmin SPECT, which are imaging techniques that create detailed pictures of the heart. The purpose of the study is to understand whether insulin resistance in the heart affects heart function and blood flow in the coronary arteries, and to see if the two medications can improve these problems in people with type 2 diabetes.

The purpose of this study is to find out how well CagriSema works in helping people lose weight compared to placebo, when used together with diet and exercise changes. The study will also look at whether people can achieve certain weight loss goals, such as losing at least five percent or twenty percent of their body weight. Additionally, the study will examine how the treatment affects waist size, blood sugar control measured by a test called HbA1c, blood pressure, and quality of life related to physical function. The safety of the treatment will be carefully monitored by tracking any unwanted effects that occur during the study, including episodes of low blood sugar.

During the study, participants will receive their assigned treatment for up to one year. Throughout this time, they will have regular visits where doctors will check their weight, blood sugar levels, blood pressure, and overall health. The study will collect information about how the treatment affects the body and whether it causes any side effects. This research aims to provide information about whether this combination treatment could be a helpful option for people with type 2 diabetes who are also struggling with excess weight.

During the study, participants will receive different combinations of semaglutide and dapagliflozin in tablet form. Some participants will take the medications separately, while others will take them combined in a single tablet. The tablets will be taken by mouth and will contain varying doses of the medications. The study will measure how the body absorbs and processes these medications by taking blood samples at specific times to check the levels of semaglutide and dapagliflozin in the blood.

The researchers will compare the concentration of each medication in the blood when taken separately versus when taken together to determine if the medications affect each other’s activity in the body. This information will help understand whether combining both medications in one tablet is as effective as taking them separately. The study involves healthy participants who will be monitored throughout the treatment period to collect the necessary data about how these medications work in the body.

During the study, participants will receive either NNC0487-0111, placebo, or standard diabetes medications including metformin and a type of medication called SGLT2 inhibitor (dapagliflozin). The treatment period will last for 36 months, during which participants will need to wear a special device that continuously monitors their blood sugar levels.

The study will measure several health indicators, including changes in blood sugar control (HbA1c), body weight, blood pressure, and various blood tests. Researchers will also monitor kidney function and check for any side effects of the treatment. This research will help determine the most effective and safe dose of the new medication for future use in treating diabetes.

The medication being tested is given as a subcutaneous injection (an injection under the skin) once weekly. During the study, participants will receive either CagriSema or placebo. The study will measure how well the medication works by tracking changes in pain levels that participants experience.

Participants will use a special rating scale to record their pain levels throughout the study. The research will also look at other health measures such as blood sugar control, blood pressure, body weight, and various blood tests to understand how the medication affects the body. The safety of the medication will be monitored by tracking any side effects that may occur during the treatment.

The study medication or placebo will be given as an injection under the skin (subcutaneous injection) once per week. The study will compare how well LY3457263 works compared to placebo in controlling blood sugar levels, specifically by measuring HbA1c (a measure of average blood sugar over the past 2-3 months).

Participants will receive either the study medication or placebo for 24 weeks. During this time, they will continue their regular diabetes medication (semaglutide or tirzepatide). The study will involve people who are overweight or have obesity and whose body weight has been stable for at least three months.

The study will last 30 weeks, during which participants will take their assigned medication once daily by mouth. The medications come in different forms – RO7795081 as hard capsules and Rybelsus as tablets. The study will measure changes in HbA1c (a measure of average blood sugar levels over the past few months) and body weight, among other health indicators.

Throughout the study period, participants will need to visit the clinic regularly for health check-ups. These visits will include blood tests to measure blood sugar control, body weight measurements, and monitoring for any side effects. The study is designed as a double-blind trial, which means neither the participants nor most of the healthcare providers will know which treatment each person is receiving.

The purpose is to see if taking insulin once a week works as well as taking it once a day for controlling blood sugar levels. The study will measure how well both treatments control blood sugar by checking HbA1c levels (a measure of average blood sugar) over 52 weeks. The medications will be given through pre-filled injection pens that patients can use at home.

During the study, participants will continue taking their other diabetes medications while adding either the weekly or daily insulin. The study will also look at how satisfied patients are with their treatment and how well they stick to their prescribed insulin schedule. Researchers will monitor participants for side effects, particularly episodes of very low blood sugar.

The purpose of this research is to examine how semaglutide, when added to standard diabetes treatment, affects certain markers of inflammation and blood vessel health in people with Type 2 diabetes who have not yet developed heart disease but may be at risk for it. The study will compare patients receiving semaglutide plus standard treatment to those receiving standard treatment alone.

During the study, participants will receive different doses of semaglutide, starting with a lower dose that will be gradually increased over time. The treatment will continue for approximately one year, during which various health measurements will be taken to monitor the effects of the medication. The maximum daily dose of semaglutide that participants may receive is 1 milligram.

The purpose of the study is to determine whether SGLT-2 inhibitors can improve the nervous system’s control of heart function and slow the progression of cardiovascular autonomic neuropathy in people with type 2 diabetes. Participants in the study will receive SGLT-2 inhibitor treatment for 6 months. During this time, they will undergo tests to measure heart rate variability (changes in time between heartbeats) and other indicators of nerve function related to the heart. Some tests will include monitoring blood sugar levels using a flash glucose monitoring system worn for 2 weeks, and a mixed meal test to assess how the body processes food.

The study is designed for adults over 45 years old with type 2 diabetes whose blood sugar levels are not optimally controlled despite current treatments. Participants will need to be on stable medication regimens for at least 3 months before joining the study.

The purpose of this research is to evaluate how well orforglipron tablets taken once daily work compared to placebo in reducing body weight in people without diabetes and improving blood sugar control in those with diabetes. The study consists of two parts: one for participants with obesity or overweight who have at least one weight-related health condition but do not have diabetes, and another for those who have both weight issues and Type 2 Diabetes.

Participants will first go through a screening period of about 4 weeks before being enrolled in the appropriate study group based on whether they have diabetes. The treatment period will last 40 weeks, during which participants will take either orforglipron or placebo. For diabetes patients, hemoglobin A1c (a measure of average blood sugar levels over 2-3 months) will be monitored to assess improvements in blood sugar control.

The purpose of the study is to investigate whether semaglutide can help heal foot ulcers in people with type 2 diabetes. Participants in the study will receive semaglutide in the form of a solution for injection, which is administered using a pre-filled pen. The study will involve different doses of semaglutide, including 0.25 mg, 0.5 mg, and 1 mg, given as a subcutaneous injection, which means it is injected under the skin.

The study will last for a period of 20 weeks, during which the healing of the foot ulcers will be monitored. The main goal is to see how many of the ulcers are completely healed after this period. Additionally, the study will look at changes in the size of the ulcers from the start to the end of the study. This research aims to provide valuable information on the potential benefits of semaglutide for patients with diabetic foot ulcers.

The purpose of the study is to see if the fecal microbiota transfer can help improve blood sugar control in these patients. Participants will be monitored over a period of time to observe changes in their blood sugar levels, specifically looking at a measure called HbA1c, which reflects average blood sugar levels over the past two to three months. The study will track these changes from the start of the study to six months later, and then continue to follow up for up to two years.

Throughout the study, participants will have regular check-ups to measure their blood sugar levels and other related health indicators. The study aims to understand how effective the fecal microbiota transfer is in helping patients achieve better control of their diabetes and to identify any factors that might predict a good response to the treatment. The safety of the treatment and its impact on the quality of life will also be evaluated.

The purpose of the study is to explore how different doses of insulin affect blood sugar levels in people with and without diabetes. Participants will receive insulin aspart through an injection, and the study will monitor how quickly their blood sugar levels return to normal after being lowered. This process is known as a “hypoglycemic clamp procedure,” which is a method used to study how the body responds to low blood sugar levels.

During the study, participants will have their blood sugar levels carefully controlled and monitored. The study will compare the insulin doses needed to lower blood sugar levels in people with diabetes to those without diabetes. It will also look at how quickly participants recover from low blood sugar levels. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the insulin aspart. The study aims to provide valuable information on how insulin aspart can be used to manage blood sugar levels effectively.

The purpose of the study is to evaluate the effectiveness of this genetic-based treatment approach. Participants will be randomly assigned to either the experimental group, receiving the personalized treatment, or the control group, receiving the optimized standard treatment. The study will last for 24 weeks, during which participants will be monitored to see if they achieve better control of their blood sugar levels. The study will also look at other health factors, such as cholesterol levels and blood pressure, to see if they improve with the treatment.

Throughout the study, the safety of the medications will be closely monitored, and any side effects will be recorded. The goal is to determine if this new approach can help more people with Type 2 Diabetes Mellitus reach their health goals and improve their overall well-being.

The study will last for 76 weeks, during which participants will receive either the BI 456906 treatment or a placebo. Throughout the study, participants will be monitored to assess changes in their body weight and other health indicators. The study aims to determine if the treatment can lead to a significant reduction in body weight and improve other health measures related to type 2 diabetes.

Participants will be evaluated on various outcomes, including the percentage change in body weight and the achievement of specific weight loss goals. The study will also look at changes in waist circumference, blood sugar levels (measured by HbA1c), and other health-related scores. This research is important for understanding how BI 456906 might help people with overweight or obesity and type 2 diabetes manage their weight and improve their overall health.

Participants in the study will be randomly assigned to receive either the high-dose treatment or a conventional therapy. The study will last for up to 24 months, during which participants will take the medications orally. The effectiveness of the treatment will be assessed by monitoring the occurrence of heart-related hospitalizations or deaths. The study will also look at other factors, such as overall hospitalizations and the levels of NT-proBNP in the blood.

The trial aims to provide valuable information on whether a more intensive treatment approach can better prevent heart issues in people with Type 2 Diabetes. By comparing the outcomes of the two treatment groups, researchers hope to determine the best strategy for reducing heart-related risks in this population. The study is expected to conclude by early 2026.

The treatments being studied include medications such as Dapagliflozin, Semaglutide, and Finerenone. Dapagliflozin is taken orally in the form of film-coated tablets, while Semaglutide is administered through subcutaneous injection, which means it is injected under the skin. Finerenone is also taken orally as a coated tablet. These medications are being tested to see if they can provide additional protection for the heart and kidneys in patients with Type 2 Diabetes.

The purpose of the study is to see if using these urine protein patterns can help guide early intervention and treatment decisions. Participants will be monitored over a period of six months to assess the feasibility of this approach. The study will look at changes in urine protein levels and kidney function to determine the effectiveness of the treatments. This research could lead to more personalized treatment plans for people with Type 2 Diabetes, potentially preventing serious complications before they occur.

The purpose of the study is to see if Dapansutrile can help lower blood sugar levels, specifically a measure called HbA1c, over a period of 26 weeks. HbA1c is a common test that shows the average level of blood sugar over the past two to three months. Participants will continue their usual diabetes treatment while taking either Dapansutrile or the placebo. The study will involve regular check-ups to monitor changes in blood sugar levels and other health indicators.

Throughout the study, participants will have their blood sugar levels checked at various intervals, and other tests will be conducted to assess how well their bodies are responding to the treatment. The study aims to provide more information on whether Dapansutrile can be an effective additional treatment for managing Type 2 diabetes.